AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Rising temperatures may make sleep apnea worse, researchers say. Editor at Large We all have cause to take climate change ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA.

Residents are learning about sleep apnea's hidden dangers as one local's experience with a CPAP machine not only transformed ...